Latest Transthyretin Stories
SAN DIEGO, Nov.
- LUNAR-101, an UNA(TM) oligomer therapeutic for transthyretin-mediated familial amyloid cardiomyopathy (TTR-FAC), exhibited in non-human primates TTR reduction greater than 90% with a single low dose
CARLSBAD, Calif., Oct. 9, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc.
CARLSBAD, Calif., July 16, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc.
CARLSBAD, Calif., June 24, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc.
- Greater than 100-fold Allele-specific silencing of V30M variant for the treatment of Familial Amyloid Polyneuropathy (TTR-FAP) - SAN DIEGO, May 13, 2014 /PRNewswire/ --
Biotech Leadership with Significant Strategic and Financial Expertise SAN DIEGO, May 6, 2014 /PRNewswire/ -- Arcturus
SAN DIEGO, April 7, 2014 /PRNewswire/ -- Arcturus Therapeutics, Inc., a preclinical-stage RNA medicines company pursuing
- LUNAR TM technology for the delivery of RNA medicines to multiple target organs and tumors will be presented SAN DIEGO, March 27, 2014 /PRNewswire/ --
- In Vivo Delivery of RNA Medicines to Multiple Tissues Utilizing its Proprietary LUNARTM Delivery Technology - SAN DIEGO, March 10, 2014 /PRNewswire/ --
- A small wooded valley; a dell.
- The protecting weather-shed built around the entrance to a house.